



Accelerated
Access
Collaborative

AAC Priorities Chief Executive's Report

NICE National Institute for
Health and Care Excellence



Medicines & Healthcare products
Regulatory Agency

**National
Voices**

amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

**Academy of
Medical Royal
Colleges**

BIA
UK BioIndustry Association

ABHI
HealthTech for Life



**UK Research
and Innovation**

NHS

The AHSN Network

NIHR | National Institute for
Health and Care Research

abpi
Bringing medicines to life

BIVDA



HM Government

Our five priorities



Research

Increase the speed, scale and diversity of research in the NHS.



Demand signalling and horizon scanning

Clearly identifying and articulating NHS needs and systematically searching for solutions.



Uptake of proven innovation

Supporting the uptake of medicines, medical devices, diagnostics and digital products.



Building innovation capacity

Supporting NHS organisations and workforce to develop, test and implement innovative solutions.



Innovator support

Making it easier to navigate the innovation ecosystem and deliver transformational commercial deals at scale.

AAC Priorities: Highlights

Chief Executive's highlights:


- NHS Innovation Showcase and Clinical Entrepreneurs Programme Big Pitch Event held on 23 Feb 2023, to help mark the NHS's 75th birthday. The event also welcomed the latest Clinical Entrepreneur Programme (CEP) cohort, taking the number supported through the programme to over 1,000 clinicians.
- Be Part of Research (BPoR), the online service that makes it easy for people to register their interest to take part in research, is now available through the NHS App. Between 1 February and 8 March over 97,000 users accessed BPoR via the NHS App; with over 35,000 of these completing registration (36% conversion rate). This is a NHS Long Term Plan commitment.
- Boost to innovative vaccine research in England following historic agreement between the UK government and BioNTech. The partnership will accelerate trials into vaccines for cancer and wider diseases, meaning cancer patients in England will get early access to trials exploring personalised mRNA therapies.
- A new Innovation and Technology Centre to be built in the UK following a strategic partnership between the UK government partners with Moderna. The state-of-the-art research and manufacturing centre will create more than 150 highly skilled jobs and have the capacity to produce up to 250 million vaccines per year in the event of a future pandemic.
- The finalised MedTech pathway mapping, undertaken in collaboration with AAC Partners including MHRA, NICE, BIVDA, ABHI, and NHSE, is ready for publication (see papers to note). Alongside this recommendations for the Medicines Pathway (archetypes) review, which are included as an appendix to Item 3 on today's agenda.

The impact of the AAC's work data highlight:

Innovator and Innovation Support

- The chart shows the cumulative in-quarter counts of innovators worked with and innovations supported by the AAC.
- The linear trend is upwards, with some variation per quarter. 2022/23 Q3 numbers are provision and subject to refinement.

Data from the AHSN network, CEP, SBRI, NIA, AI Award, MTFM, and RUP




The Impact of the AAC's work

Ensuring access through the MedTech Funding Mandate (MTFM)

- The MedTech Funding Mandate (MTFM) policy aims to increase the sustainability of innovative product adoption, moving away from central funding to the local adoption of products, alongside implementation support. It is a NHS Long Term Plan commitment, that replaced the Innovation and Technology Payment.
- The chart shows the proportion of eligible sites adopting selected technologies at baseline compared to the latest quarter (Q3 2022/23). It demonstrates that following the change in approach, adoption has in most cases increased.
- In addition to the change in approach, a strong collaboration is emerging between AAC partners, including NHS England, AHSNs, NICE and NHS Supply Chain. This partnership is reviewing the 'criteria' to ensure the best, NICE-recommended, technologies are being identified for MTFM.
- Latest intelligence suggests that funding is less of a barrier to adoption of MedTech. To reduce the number of asks that the system faces as it recovers from the Covid pandemic no new products will be added to MTFM in 2023/24. A range of products will be considered for inclusion in 2024/25, ensuring the mandate remains effective.

Spotlight on addressing health inequalities

- Sickle Cell Disease: The Medtech Funding Mandate policy and NHSE's Specialised Commissioning have enabled greater for NHS patients to Automated Red Cell Exchange using the NICE approved Spectra Optia Apheresis
- This enables patients living with Sickle Cell Disease to have a treatment that is faster, better tolerated and more cost effective than alternatives
- In 22/23 to date access has scaled from being available in 17% of sites to 43% of sites with business cases being reviewed in every site.
- **The level of patent uptake anticipated after three years has been exceeded in under one year.**



Notes:

Stage 4: there is a local decision to adopt a technology

Stage 5 adoption has occurred.

Some products have been supported by previous AAC programmes

The Impact of the AAC's work


Innovation for Health Inequalities Programme (InHIP)

- The AAC Board approved a shift in focus from single technologies adoption to a focus on tackling health inequalities. Following this, the Innovation for Health Care Inequalities Programme (InHIP) was developed.
- 38 out of 42 Integrated Care Systems (ICSs) are running 39 projects to reduce local health inequalities. ICSs received up to £100k in funding to participate in phase 1 funded projects that commenced in November or December 2022. They represent the opportunity to progress understanding and action on health inequalities. The chart to the right shows the clinical areas of the phase 1 projects. The programmes identified fit across five clinical themes: CVD, respiratory, cancer, maternity, and mental, with over 70% in CVD.
- The majority of these projects will move into delivery phase from April 2023. A measurement framework has been developed and piloted with a retrospective capture of data for Q3 2022/23. Measurement will cover access and experience. The feasibility of reporting outcomes is being investigated.

Example project: Hertfordshire and West Essex ICS project supported by Eastern AHSN

This project aims to improve detection and management of atrial fibrillation (AF) in deprived populations in the Stevenage locality (Stevenage North & South PCNs). Particular emphasis will be working with black and ethnic minority communities. CVD Prevent data show that people from these communities with AF are less likely to be appropriately managed. This will be delivered with the use of existing community relationships and further engagement with Voluntary, Community, Faith, and Social Enterprise sectors (VCSFE) to co-develop a community outreach approach with the representatives from CORE20PLUS populations.

Patients will be educated on signs and symptoms of AF and CVD and will be clinically accessed before referring symptomatic patients into primary care for management and DOAC prescribing (includes Edoxaban [TA355](#)). The community events will also be used for raising awareness of signs and symptoms of AF, management of AF and consequences.



Portfolio Delivery Overview

Delivery against AAC priorities has continued, alongside scoping the next set of programmes and actions

	 Research		 Demand signalling & horizon scanning		 Uptake of proven innovation		 Building innovation capacity		 Innovator support		 Cross cutting	
Rating	Last Period	This Period	Last Period	This Period	Last Period	This Period	Last Period	This Period	Last Period	This Period	Last Period	This Period
Key updates	<ul style="list-style-type: none"> Publication of ICS Research Guidance and the Increasing Diversity in Research Participation: A good practice guide for engaging with underrepresented groups The 2023/24 Planning Guidance included research for the first time. Link to <i>Be Part of Research</i> (BPoR) included in the NHS App, resulting in over 29,000 new volunteers in first month Two pilots exploring the use of NHS touchpoints to increase registration on BPoR underway National Contract Value Review (NCVR), second round of data collection began and round table held to explore next steps for NCVR and wider commercial contract research set up efficiencies Reset: A joint DHSC/NHSE letter requesting sites to expedite commercial contract research, issued on 13 March 		<ul style="list-style-type: none"> As a direct result of the Demand Signalling reports, AAC partners programmes have mobilised to award the following: <ul style="list-style-type: none"> Stroke – 16 projects funded via SBRI Learning Disability and Autism – 5 projects funded, £470k allocated Mental Health – 3 projects funded, £1.3m allocated Horizon scans completed: <ul style="list-style-type: none"> Diagnostics at home: A. COPD (24 technologies identified). B. Asthma (32 technologies identified) Immuno-oncology - may support NICE with topic selection challenges Repurposed medicines – scan implemented as BAU 		<ul style="list-style-type: none"> MedTech innovation pathway review, co-led with ABHI, concluded and published in March 2023 ICS and medicines archetypes workstreams (as part of the medicines pathway evaluation programme) delivered in line with programme timelines. Round 3 of AI in Health and Social Care Award announced in Mar 23, with £16m of funding for 9 innovators, including for Colorectal Cancer detection and Breast histopathology analysis Approval of Spectra Optia business case to expand provision of this specialised MTFM technology to SE London for Sickle Cell patients 		<ul style="list-style-type: none"> 12-month AHSN relicence agreed by NHSE, with contract extension and funding award letters issued. Formal business planning for AHSN extension commenced in January alongside a new AHSN review process for 24/25 onward. Welcomed cohort 7 of future entrepreneurs onto the Clinical Entrepreneur Programme (CEP), taking the number of staff supported to over 1,000 – boosting our workforce capability to develop and spread innovation 		<ul style="list-style-type: none"> Since successful public launch of the NHS Innovation Service in July 2022, over 600 innovators have registered on the service, with over 160 receiving active support and two technologies selected for NICE guidance. NHS Innovation Showcase and Clinical Entrepreneurs Programme Big Pitch Event held on 22 Feb 2023, to help mark the NHS' 75th birthday. £19.4m of funding allocated across 7 SBRI competitions, including over £5m to improve stroke diagnosis, rehabilitation and living post-stroke. 		<ul style="list-style-type: none"> Net zero criteria developed for AAC programmes and agreed for the NHS Innovation service. Net zero performance metrics project approved and started with the AHSN to define an environmental assessment framework for innovations Work to develop a framework to apply patient insight to accelerate spread and adoption planning is underway On-going PPI input to the ICS REND programme and engaging diverse communities, and the MTFM programme around improving equity of access to innovations 	
Next steps	<ul style="list-style-type: none"> Continue operational policy support for Strategic Commercial Partnership Work with DHSC & others on the response to the Lord O'Shaughnessy review Publication of the evidence review exploring wider benefits of research Continued work on Research Reset programme 		<ul style="list-style-type: none"> Developing a new R&I priority setting approach Scoping early diagnostics scan for Alzheimer's Disease Diagnostics at home audiology horizon scan Continue to develop and finalise data-sharing agreement with NIHRIO and AAC partners. 		<ul style="list-style-type: none"> Ongoing support to SBRI and AI Award winners Medicines pathway roadmap report due in Q1 FY 23/24. 		<ul style="list-style-type: none"> NHS CEP InSites report due in early Q1 FY 23/24. 		<ul style="list-style-type: none"> Agree programme of work to be undertaken in collaboration with Commercial Directorate The NHS Innovation Service to manage and onboard a prioritised pipeline of future support organisations 		<ul style="list-style-type: none"> New AAC information portal to be further refined in 23/24. Publication of the end of year PPI report for 22/23 Test net zero criteria with stakeholders and plan innovation support for 2023/24 	